The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimers disease

Cholinesterase inhibitors (ChEIs) are used for symptomatic treatment of Alzheimers disease. These drugs have vagotonic and anti-inflammatory properties that could be of interest also with respect to cardiovascular disease. This study evaluated the use of ChEIs and the later risk of myocardial infarction and death. The cohort consisted of 7073 subjects (mean age 79 years) from the Swedish Dementia Registry with the diagnoses of Alzheimers dementia or Alzheimers mixed dementia since 2007. Cholinesterase inhibitor use was linked to diagnosed myocardial infarctions (MIs) and death using national registers. During a mean follow-up period of 503 (range 02009) days, 831 subjects in the cohort suffered MI or died. After adjustment for confounders, subjects who used ChEIs had a 34 lower risk for this composite endpoint during the follow-up than those who did not [hazard ratio (HR) 0.66, 95 confidence interval (CI) 0.560.78]. Cholinesterase inhibitor use was also associated with a lower risk of death (HR: 0.64, 95 CI: 0.540.76) and MI (HR: 0.62, 95 CI: 0.400.95) when analysed separately. Subjects taking the highest recommended ChEI doses (donepezil 10 mg, rivastigmine 6 mg, galantamine 24 mg) had the lowest risk of MI (HR: 0.35, 95 CI: 0.190.64), or death (HR: 0.54, 95 CI: 0.430.67) compared with those who had never used ChEIs. Cholinesterase inhibitor use was associated with a reduced risk of MI and death in a nationwide cohort of subjects diagnosed with Alzheimers dementia. These associations were stronger with increasing ChEI dose.